For the first time in the history of Alzheimer’s research, scientists are not just slowing the disease — they are beginning to reverse its damage, prevent its formation decades before symptoms appear, and repurpose cheap, widely available drugs to fight it. A January 2026 Harvard study found that lithium orotate actually restored lost synapses and reversed Alzheimer’s pathology in mouse models, while a Northwestern University team discovered that a common anti-seizure medication can stop toxic amyloid plaques from ever forming. These are not incremental gains.
They represent a fundamental shift in how medicine approaches a disease that affects 7.2 million Americans over 65 and costs the nation $384 billion a year. The treatment landscape has changed dramatically since the FDA approved the first amyloid-targeting therapies — Leqembi in 2023 and Kisunla in 2024. But the real story in 2026 is what is coming next: drugs that work through entirely different mechanisms, clinical trials launching this spring, and a growing recognition that Alzheimer’s may be preventable if caught early enough. This article covers the current state of approved treatments, the most promising next-generation therapies, the surprising old drugs being repurposed for dementia, and what all of this means for patients and families navigating the disease right now.
Table of Contents
- What New Alzheimer’s Treatments Are Changing How We Think About the Disease?
- How Current FDA-Approved Therapies Work — and Where They Fall Short
- The Anti-Seizure Drug That Could Prevent Alzheimer’s Before It Starts
- Drug Repurposing — Could a Shingles Vaccine or Viagra Help Fight Dementia?
- Next-Generation Therapies and the Risks You Should Know About
- What Harvard’s Lithium Orotate Discovery Could Mean for Treatment
- The Road Ahead — What Families and Caregivers Should Watch For
- Conclusion
- Frequently Asked Questions
What New Alzheimer’s Treatments Are Changing How We Think About the Disease?
For decades, the dominant framework for Alzheimer’s was straightforward and bleak: amyloid plaques build up in the brain, neurons die, cognition declines, and there is nothing medicine can do about it. The FDA-approved drugs that existed before 2023 managed symptoms at best. That framework is now being dismantled from multiple directions. Leqembi (lecanemab) and Kisunla (donanemab) proved that clearing amyloid plaques from the brain can slow cognitive decline in early-stage Alzheimer’s patients. Kisunla went a step further — it became the first amyloid-targeting therapy with evidence supporting the idea that treatment can actually be stopped once plaques are sufficiently cleared, rather than continued indefinitely. But the newer research goes beyond plaque clearance entirely.
The Harvard lithium orotate study, led by researcher Bruce Yankner, found that lithium is naturally depleted in the brains of people with mild cognitive impairment and Alzheimer’s because amyloid plaques bind and sequester the metal. When researchers administered lithium orotate to mouse models, the compound did not just slow decline — it prevented and reversed Alzheimer’s pathology and restored synapses. Clinical trials are expected to begin in spring 2026 at Mass General and Brigham and Women’s Hospital. Meanwhile, Indiana University researchers identified a completely new drug target: an enzyme called IDOL that, when removed from neurons, substantially reduces amyloid plaques and may provide resilience against disease progression without requiring the antibody infusions that current treatments demand. The shift is philosophical as much as pharmacological. We are moving from “manage the inevitable” to “intervene at the root cause, possibly decades before symptoms appear.” That changes how patients, caregivers, and doctors should think about early screening, treatment planning, and long-term hope.
How Current FDA-Approved Therapies Work — and Where They Fall Short
Leqembi and Kisunla represent genuine medical progress, but they come with significant limitations that patients and families need to understand clearly. Both are monoclonal antibodies designed to bind to and clear amyloid-beta plaques from the brain. Leqembi, approved in 2023, originally required biweekly IV infusions at a clinic — a substantial burden for patients and caregivers. The FDA has since approved an at-home injectable form, and a decision on approving starter doses for home use is expected in May 2026. Kisunla, approved in 2024 and recently granted EU approval, offers a different advantage: because it is the first therapy where evidence supports stopping treatment once plaques are cleared, it can reduce both the total cost and the number of infusions a patient needs. However, both drugs carry a meaningful safety risk. Patients taking either medication face a 4.35 times higher risk of amyloid-related imaging abnormalities, known as ARIA, compared to placebo.
ARIA can manifest as brain swelling or microbleeds, and while many cases are asymptomatic, some are serious. This means regular MRI monitoring is essential during treatment, adding to the logistical and financial burden. Both drugs are also only approved for early-stage Alzheimer’s — they do not help patients with moderate or advanced dementia, which excludes the majority of people currently living with the disease. The cost remains another barrier. Even with Kisunla’s stop-treatment advantage, these are expensive biologics. With total Alzheimer’s care costs projected to reach nearly $1 trillion by 2050, the question of who can access these treatments and for how long is not academic. Nearly 12 million Americans already provide unpaid caregiving for people with Alzheimer’s, contributing over 19 billion hours valued at $413 billion in 2024 alone. Treatments that require clinic visits, MRI monitoring, and specialty pharmacy access are not equally available to a family caregiver in rural Arkansas and one in Boston.
The Anti-Seizure Drug That Could Prevent Alzheimer’s Before It Starts
One of the most striking findings of 2026 came not from a pharmaceutical company but from a university laboratory. Researchers at Northwestern University discovered that levetiracetam — a cheap, decades-old anti-seizure drug already widely prescribed for epilepsy — can prevent neurons from producing the toxic amyloid-beta 42 protein that forms the plaques associated with Alzheimer’s. The study, published February 11, 2026, in Science Translational Medicine, found that levetiracetam works by binding to a protein called SV2A in synaptic vesicles. This binding slows the recycling process and keeps amyloid precursor protein on the cell surface, away from the pathway that produces the dangerous form of amyloid. The implications are enormous, but so is the limitation. For levetiracetam to work as a preventive measure, it would likely need to be taken very early — potentially 20 years before current diagnostic tests can detect abnormal amyloid levels.
That means it would not help anyone who already has dementia or even mild cognitive impairment. It is a prevention play, not a treatment, and it depends on developing far better early-detection methods than currently exist. For families watching a loved one decline right now, this research offers hope for future generations but not an immediate answer. Still, the significance should not be understated. If we can identify people at high genetic risk for Alzheimer’s and begin a cheap, well-understood medication decades before symptoms appear, we could prevent the disease in a meaningful percentage of cases. That is a fundamentally different proposition than clearing plaques after they have already caused damage.
Drug Repurposing — Could a Shingles Vaccine or Viagra Help Fight Dementia?
Some of the most intriguing Alzheimer’s research in 2026 involves drugs that already exist, are already approved for other conditions, and could potentially be deployed far more quickly and cheaply than novel therapies. A University of Exeter study, funded by the Alzheimer’s Society, convened an international expert panel to review 80 existing drugs for their potential against dementia. The top three candidates they identified were Zostavax (the shingles vaccine), sildenafil (sold as Viagra), and riluzole (a drug used for motor neurone disease). The evidence behind these candidates varies. Previous observational data suggests that people who received the shingles vaccine were roughly 16 percent less likely to develop dementia — a correlation that researchers want to test in large-scale randomized trials. Sildenafil has the advantage of being able to cross the blood-brain barrier, and preclinical evidence suggests it may reduce the buildup of toxic tau protein, the other hallmark of Alzheimer’s pathology alongside amyloid.
Riluzole works through yet another mechanism. The tradeoff with repurposed drugs is straightforward: they are cheaper and their safety profiles are well understood, but the evidence for their effectiveness against Alzheimer’s is still largely observational or preclinical. A randomized controlled trial could confirm or refute these findings, and researchers are now calling for exactly that. The comparison to novel therapies is instructive. Leqembi and Kisunla cost tens of thousands of dollars per year and require specialized medical infrastructure. A repurposed generic drug, if proven effective, could be prescribed by any physician at a fraction of the cost. For a disease projected to affect nearly 13 million Americans by 2050, scalability matters as much as efficacy.
Next-Generation Therapies and the Risks You Should Know About
Beyond the currently approved drugs and the repurposing candidates, a new generation of amyloid-targeting therapies is moving through clinical trials. Trontinemab has recently advanced into Phase III clinical trials. Eli Lilly’s remternetug is being tested in over 1,600 participants, with Phase III results on plaque clearance expected in March 2026. Remternetug is being studied in both IV and injectable versions, which could expand access if approved. But the enthusiasm around these drugs must be tempered with caution. The 4.35-fold increased risk of ARIA seen with current anti-amyloid therapies is a class-wide concern, not a quirk of one particular drug.
Until next-generation therapies demonstrate a meaningfully better safety profile, patients and doctors will need to weigh the benefit of slowed cognitive decline against the risk of brain swelling and microbleeds. This is especially important for patients who carry the APOE4 gene variant, which is associated with a higher risk of both Alzheimer’s and ARIA. There is also a broader concern about the amyloid hypothesis itself. While clearing plaques does appear to slow decline, the effect sizes in clinical trials have been modest. Some researchers argue that amyloid is a necessary part of the Alzheimer’s puzzle but not the whole picture, which is why research into alternative targets — like Indiana University’s work on the IDOL enzyme and Harvard’s lithium orotate findings — is so important. Patients and families should be wary of any framing that presents amyloid-clearing drugs as a cure. They are a meaningful step forward, but they are not the end of the road.
What Harvard’s Lithium Orotate Discovery Could Mean for Treatment
The Harvard lithium orotate study deserves special attention because it challenges a core assumption about Alzheimer’s: that neuronal damage, once done, is irreversible. Bruce Yankner’s team found that lithium orotate did not just halt disease progression in mouse models — it restored synapses that had already been lost. If this finding translates to humans, it would be the first treatment to actually repair Alzheimer’s-related brain damage rather than merely slow its accumulation.
The researchers have been appropriately cautious, explicitly stating that they do not recommend lithium orotate to patients until human trials confirm safety and efficacy. This is important, because lithium compounds are readily available as supplements and the temptation to self-medicate will be strong. Lithium has a narrow therapeutic window and can cause serious side effects at higher doses, including kidney damage and thyroid dysfunction. The clinical trials launching in spring 2026 at Mass General and Brigham and Women’s Hospital will be critical in determining whether the promise seen in mice holds up in human patients.
The Road Ahead — What Families and Caregivers Should Watch For
The next 12 to 18 months will be among the most consequential in Alzheimer’s research history. By the end of 2026, we should have Phase III results from remternetug, initial data from the lithium orotate human trials, and an FDA decision on at-home starter doses for Leqembi. If even one of these developments delivers on its promise, the standard of care for Alzheimer’s will shift significantly. Nearly two-thirds of Americans with Alzheimer’s are women, and the caregiver burden falls disproportionately on families with fewer resources — any treatment that is cheaper, easier to administer at home, or effective at earlier stages has outsized implications for equity.
For families navigating Alzheimer’s today, the practical takeaway is this: early diagnosis matters more than it ever has. The most promising treatments — both approved and experimental — work best in early-stage disease or even before symptoms appear. Talk to a neurologist about screening if there is a family history. Stay informed about clinical trial enrollment, particularly for the lithium orotate and repurposed drug studies. And be skeptical of anyone selling certainty — what we have right now is genuine, hard-won progress, not a cure.
Conclusion
The Alzheimer’s treatment landscape in 2026 looks nothing like it did even three years ago. We have two FDA-approved therapies that clear amyloid plaques, a pipeline of next-generation drugs advancing through trials, a cheap anti-seizure medication that may prevent plaque formation decades before symptoms, a Harvard-discovered compound that restored lost synapses in animal models, and a shortlist of repurposed drugs that could be deployed widely if randomized trials confirm their benefit. Each of these approaches attacks the disease from a different angle, and together they represent the most diverse and promising set of options patients have ever had.
None of this erases the reality that 7.2 million Americans are living with Alzheimer’s dementia today, or that the disease still has no cure. But the question has shifted from whether we can intervene in Alzheimer’s progression to how early, how effectively, and how accessibly we can do so. For the nearly 12 million unpaid caregivers and the millions of families watching this disease take someone they love, that shift — from helplessness to active, evidence-based hope — matters enormously.
Frequently Asked Questions
Are the new Alzheimer’s drugs a cure?
No. Leqembi and Kisunla slow cognitive decline in early-stage Alzheimer’s but do not stop or reverse the disease. The lithium orotate research showed reversal in mouse models, but human trials have not yet begun. No currently available treatment is a cure.
Who is eligible for Leqembi or Kisunla?
Both drugs are approved for patients with early-stage Alzheimer’s disease who have confirmed amyloid plaques. They are not indicated for moderate or advanced dementia. A physician will typically confirm amyloid status through a PET scan or spinal fluid test before prescribing.
What is ARIA and how dangerous is it?
ARIA stands for amyloid-related imaging abnormalities, which can include brain swelling or small bleeds detectable on MRI. Patients on anti-amyloid therapies have a 4.35 times higher risk of ARIA than those on placebo. Many cases are mild or asymptomatic, but some can be serious, which is why regular MRI monitoring is required during treatment.
Should I take lithium orotate supplements for Alzheimer’s prevention?
No — not yet. The Harvard researchers who conducted the study have explicitly stated they do not recommend lithium orotate to patients until human clinical trials, expected to begin spring 2026, confirm safety and dosing. Lithium has a narrow therapeutic window and can harm the kidneys and thyroid at improper doses.
Can the shingles vaccine prevent Alzheimer’s?
Observational data suggests Zostavax recipients were approximately 16 percent less likely to develop dementia, but this has not been confirmed in a randomized controlled trial. Researchers are calling for large-scale trials to determine whether this association is causal.
When will new treatment options become available?
Phase III results for remternetug are expected in March 2026, lithium orotate clinical trials are slated for spring 2026, and an FDA decision on Leqembi at-home starter doses is expected by May 2026. Results from these milestones will shape the next wave of available treatments.
